[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336055-105":59,"doc-detail-336055-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","a-gut-microbial-signature-for-combination-immune-checkpoint-blockade-across-cancer-types","A gut microbial signature for combination immune checkpoint blockade across cancer types","","Immune checkpoint blockade targeting PD-1 and CTLA-4 can produce notable but highly variable responses across cancers. The study evaluates whether gut microbiome features can serve as generalizable predictors. Deep shotgun metagenomic sequencing of baseline fecal samples from a phase 2 trial discovery cohort shows that strain-resolved microbial abundances improve machine-learning prediction of ICB response and 12-month progression-free survival. A validation meta-analysis supports cross-cancer, cross-country validity of strain-response signatures when ICB regimens match, implying regimen-tailored microbiome diagnostics or therapeutics.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-gut-microbial-signature-for-combination-immune-checkpoint-blockade-across-cancer-types/336055/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-gut-microbial-signature-for-combination-immune-checkpoint-blockade-across-cancer-types/336055.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main goal of the study regarding immune checkpoint blockade?","Question",{"text":113,"@type":114},"To determine whether baseline gut microbial signatures can predict responses to combination immune checkpoint blockade across different cancer types.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why do the authors focus on strain-resolved microbial abundances?",{"text":118,"@type":114},"Because species-level taxonomic biomarkers may be too imprecise to capture microbial traits linked to response, while strain-level differences better reflect functional variation.",{"name":120,"@type":111,"acceptedAnswer":121},"When do strain–response signatures generalize across cancer types and countries?",{"text":122,"@type":114},"They generalize only when the training and test cohorts use concordant ICB regimens, such as anti-PD-1 monotherapy or combination anti-PD-1 plus anti-CTLA-4.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},336055,1790121879,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":4},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","nature medicine  \nArticle [https://doi.org/10.1038/s41591-024-02823-z](https://doi.org/10.1038/s41591-024-02823-z)  \nA gut microbial signature for combination immune checkpoint blockade across cancer types  \nReceived: 23 June 2023  \nAccepted: 12 January 2024  \n\n| Published online: 1 March 2024 |\n| --- |\n|  Check for updates |\n\nAshray Gunjur  1,2 , Yan Shao  1, Timothy Rozday1, Oliver Klein3,4,5, Andre Mu1,6, Bastiaan W. Haak1,7, Ben Markman  8,9,10, Damien Kee4,11,12, MatteoS. Carlino13,14, Craig Underhill  15,16, Sophia Frentzas8, Michael Michael11,17, Bo Gao13, Jodie Palmer3, Jonathan Cebon3,4, Andreas Behren  3, David J. Adams  2,18 & Trevor D. Lawley  1,18  \nImmune checkpoint blockade (ICB) targeting programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte protein 4 (CTLA-4) can induce remarkable, yet unpredictable, responses across a variety of cancers. Studies suggest that there is a relationship between a cancer patient’s gut microbiota composition and clinical response to ICB; however, defining microbiome-based biomarkers that generalize across cohorts has been challenging. This may relate to previous efforts quantifying microbiota to species (or higher taxonomic rank) abundances, whereas microbial functions are often strain specific. Here, we performed deep shotgun metagenomic sequencing of baseline fecal samples from a unique, richly annotated phase 2 trial cohort of patients with diverse rare cancers treated with combination ICB (n = 106 discovery cohort). We demonstrate that strain-resolved microbial abundances improve machine learning predictions ofICB response and 12-month progression-free survival relative to models built using species-rank quantifications or comprehensive pretreatment clinical factors. Through a meta-analysis of gut metagenomes from a further six comparable studies (n = 364 validation cohort), we found cross-cancer (and cross-country) validity of strain–response signatures, but only when the training and test cohorts used concordantICB regimens (anti-PD-1 monotherapy or combination anti-PD-1 plus anti-CTLA-4).  \nThis suggests that future development of gut microbiome diagnostics or therapeutics should be tailored according to ICB treatment regimen rather than according to cancer type.  \nThe past decade has seen an‘immuno-oncology revolution’ largely driven by the rapid uptake of immune checkpoint blockade (ICB) agents targeting cytotoxic T lymphocyte protein 4 (CTLA-4), programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1, the ligand  \nof PD-1). Combination ICB (CICB) targeting both PD-1 and CTLA-4 has demonstrated synergistic antitumor activity preclinically1 and is now an approved standard of care for patients with diverse cancers, including melanoma2, clear-cell renal cell carcinoma3, non-small cell lung cancer  \nA full list of affiliations appears at the end of the paper. e-mail: [ag35@sanger.ac.uk](ag35@sanger.ac.uk); [tl2@sanger.ac.uk](tl2@sanger.ac.uk)  \n(NSCLC)4, mesothelioma5 and hepatocellular carcinoma6. However, this success is tempered by the unpredictable nature of responses (seen in only 20–60% of patients across these cancer indications7) and the more frequent severe immune-related adverse effects experienced with CICB when compared to anti-PD-1 or anti-PD-L1 monotherapy8. Thus, despite the promise it offers, the judicious use ofCICBis paramount. Additionally, predictive biomarkers for tumor response and/or toxicity would be highly valuable to guide patient management.  \nCurrently approved tumor-agnostic biomarkers for PD-1 blockade include tumor mutational burden and mismatch repair deficiency9; however, both have limitations andrelyon available, contemporaneous tumor tissue. A promising‘tumor-extrinsic’ avenue for predicting ICB response and/or toxicity a priori is assessing a patient’s baseline gut microbiome composition, referring to the community of microbiota (predominantly bacteria) resident within the gastrointestinal tract. Culture-free me","cbCaijAL8LJ0ffu7","https://ap.wps.com/l/cbCaijAL8LJ0ffu7","pdf",10157627,28,"English","# Introduction\n# Results\n## Clinical characteristics of the CA209-538 cohort","[{\"question\":\"What is the main goal of the study regarding immune checkpoint blockade?\",\"answer\":\"To determine whether baseline gut microbial signatures can predict responses to combination immune checkpoint blockade across different cancer types.\"},{\"question\":\"Why do the authors focus on strain-resolved microbial abundances?\",\"answer\":\"Because species-level taxonomic biomarkers may be too imprecise to capture microbial traits linked to response, while strain-level differences better reflect functional variation.\"},{\"question\":\"When do strain–response signatures generalize across cancer types and countries?\",\"answer\":\"They generalize only when the training and test cohorts use concordant ICB regimens, such as anti-PD-1 monotherapy or combination anti-PD-1 plus anti-CTLA-4.\"}]","A gut microbial signature for combination immune checkpoint blockade across cancer types | PDF",1790013402,71]